Clinical trial
Gefitinib in Treating Children With Refractory Solid Tumors
NCT00040781 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00040781 |
|---|---|
| Title | Gefitinib in Treating Children With Refractory Solid Tumors |
| Official title | A Phase I Study Of ZD1839 (Iressa TM), An Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, In Children With Refractory Solid Tumors |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Childhood Solid Tumor, Protocol Specific |
| Intervention type | Drug, Other |
| Interventions | gefitinib, pharmacological study, laboratory biomarker analysis |
| Enrollment | 45 |
| Start date | Jun 1, 2002 |
| Primary completion | Oct 1, 2004 |
| First posted | Jan 27, 2003 |
| Last update posted | Jan 23, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: